Genomenon collaborates with rare disease foundations on drug development

The AI-driven genomics company Genomenon has announced that it will work with COMBINEDBrain, SynGAP Research Fund and SLC-6A1 Connect.

COMBINEDBrain is a 501(c)(3) company focused on developing new treatments for neurodevelopmental disorders. COMBINEDBrain partners with more than 30 neurodevelopmental rare disease foundations, including SynGAP Research Fund and SLC6A1 Connect. “Our collaboration with Genomenon represents a big step toward finding a cure for genetic developmental disorders,” said COMBINEDBrain founder Dr. Terry Jo Bichell in a news release. “We are excited for what the future holds.”

The SynGAP Research Fund is a 501(c)(3) public charity focused on improving the quality of life of people with SYNGAP1-related non-syndromic intellectual disability, a rare genetic disorder associated with an SYNGAP1 gene variant. “Kids with SYNGAP1 are disabled for life and require huge investments and sacrifices from their families,” said Mike Gragli, SYNGAP1 foun…

Read more
  • 0